ALK-N001

ALK-N001 · Zhejiang Anglikang Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ALK-N001, covering 2026-04-13 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors [Phase 1]